(Press-News.org) Barcelona, 03 October 2013. This international trial, published in The Lancet, is one of the largest phase III trials in second-line treatment of gastric cancer. Standard care for advanced gastric cancer, known as first-line treatment, is based on chemotherapy, but it only offers a median survival of 8 to 10 months.
The trial investigated the use of ramucirumab, an antibody developed to treat solid tumours that targets Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2), a key receptor in the angiogenesis process. It showed that ramucirumab effectively inhibits a group of proteins that stimulate angiogenesis, a physiological process whereby new blood vessels are formed from pre-existing vessels, which plays a key part in malignant tumour growth. These proteins induce capillary growth in the tumour, supplying the nutrients that it needs.
The clinical trial was conducted on 355 patients with advanced gastric cancer, 238 of whom received treatment with ramucirumab, while 117 received placebo. All patients also received best supportive care. The ramucirumab treatment group showed improved median survival (5.2 months versus 3.8 months in the other group), better tumour control and a noteworthy reduction in the risk of disease progression or death. After six months of treatment with ramucirumab, patient survival in this group was 40%, while response to standard treatment was notably lower (below 20%).
Dr Josep Tabernero, Head of the Medical Oncology Department at the Vall d´Hebron University Hospital, Director of the Vall d´Hebron Institute of Oncology (VHIO), and one of the co-authors of this study, confirmed that "the results of this study are important for several reasons. First, the study revives the idea that inhibition of the angiogenesis process plays an important role in gastric cancer, which can be used to achieve results in these patients. This is important because previous studies with the drug bevacizumab - which inhibits the vascular endothelial growth factor (VEGF) - did not show any significant benefit in this disease. Second, the study results open new avenues for patients with gastric cancer, offering more treatment options. Thirdly, new studies combining ramucirumab with chemotherapy drugs in gastric cancer are making us very optimistic about the outcome of these combinations, because of the synergies between the drugs. This is likely to change the way we treat gastric cancer in the future."
A very aggressive cancer
Gastric cancer is the fourth most common cancer worldwide, and the second leading cause of cancer-related death. In Western countries, most patients with gastric adenocarcinoma have advanced disease at diagnosis, and treatment options are limited.
Following first-line gastric cancer chemotherapy, with a median survival of 8 to 10 months, most national medicines agencies have approved second-line treatment in patients with gastric cancer. However, we still need specific new systemic agents, based on our underlying understanding of gastric cancer biology, to improve outcomes in patients with advanced disease. This study opens a new avenue in second-line treatment of this type of cancer.
###
The phase III study, published in the prestigious scientific journal, The Lancet, in which researchers at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO) have participated, shows that an antibody (ramucirumab) inhibits the action of various proteins involved in tumour growth, prolonging survival of patients with advanced gastric cancer.
Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death. In Western countries, most patients with gastric cancer have advanced disease at diagnosis, and treatment options are limited. This study opens a new avenue in second-line treatment of this type of cancer.
More Information:
Amanda Wren, Communication Manager
Vall d´Hebron Institute of Oncology
Tel: +34 695207886
Email: awren@vhio.net
International study shows efficacy of new gastric cancer drug
The phase III study published in the The Lancet shows that an antibody (ramucirumab) inhibits the action of various proteins involved in tumour growth, prolonging survival of patients with advanced gastric cancer
2013-10-03
ELSE PRESS RELEASES FROM THIS DATE:
Newly identified biomarkers help predict outcome in deadly lung disease
2013-10-03
New Haven, Conn. – A Yale-led study has identified a gene expression profile that can predict outcomes and lead to better treatment for one of the most lethal lung diseases, idiopathic pulmonary fibrosis (IPF). The study appears in Science Translational Medicine.
IPF causes progressive scarring of the lungs, leading to cough, shortness of breath, and potentially death. In most cases, the cause cannot be identified, and there is no cure other than a lung transplant. While some patients experience a progressive course that leads to death within one to two years, others ...
Long-term cognitive impairment too common after critical illness
2013-10-03
Patients treated in intensive care units across the globe are entering their medical care with no evidence of cognitive impairment but oftentimes leaving with deficits similar to those seen in patients with traumatic brain injury (TBI) or mild Alzheimer's disease (AD) that persists for at least a year, according to a Vanderbilt study published today in the New England Journal of Medicine.
The study, led by members of Vanderbilt's ICU Delirium and Cognitive Impairment Group, found that 74 percent of the 821 patients studied, all adults with respiratory failure, cardiogenic ...
High-dose statins reduce gum inflammation in heart disease patients
2013-10-03
WASHINGTON (Oct. 2, 2013) — Statins, commonly prescribed medications for lowering cholesterol, also reduced inflammation associated with gum disease in a new study published today in the Journal of the American College of Cardiology. The study suggests that steps taken to reduce gum disease may also reduce inflammation in the arteries and vice versa.
"Periodontal disease is characterized by chronic gum inflammation and affects approximately 50 percent of the U.S. adult population," said Ahmed Tawkol, MD, co-director of the Cardiac Imaging Trials Program at Massachusetts ...
McMaster lab develops new tuberculosis vaccine
2013-10-03
Hamilton, ON (Oct. 2, 2013) -- A tuberculosis vaccine developed at McMaster University offers new hopes for the global fight against tuberculosis.
"We are the first to have developed such a vaccine for tuberculosis," said Dr. Fiona Smaill, professor and chair of the Department of Pathology and Molecular Medicine of the Michael G. DeGroote School of Medicine at McMaster. She led the phase one clinical study published today in the journal Science Translational Medicine.
The vaccine, based on a genetically modified cold virus, was developed in the lab of Zhou Xing, professor ...
In spectrum of ACL injury treatment, new study reveals cost savings for those who need surgery
2013-10-03
Rosemont, Ill – In late summer and early fall when youth and college sports begin, it's a similar refrain: a star on the varsity basketball team tore her anterior cruciate ligament (ACL) and is out for the season after surgery. A college football game stopped as a defensive safety hobbles off the field with an ACL injury. Annually in the U.S., more than 200,000 ACL injuries are reported, often by active young adult and adolescent athletes, though they can occur at any age. Depending on the severity of the injury, treatment may include rehabilitation or surgery and rehabilitation, ...
Specialized intestinal cells cause some cases of Crohn's disease
2013-10-03
Scientists have discovered that Crohn's disease, the inflammatory bowel disorder, can originate from specialised intestinal cell type called Paneth cells. As such, they propose that small intestinal Crohn's disease might be a specific disorder of this cell type, providing a possible new target for treatments. The study, by researchers from the University of Cambridge and Harvard University, was published today in the journal Nature.
"If we are able to break down Crohn's disease into subsets by understanding the underlying mechanisms, which we have done here, we hope to ...
Red wine chemical remains effective against cancer after the body converts it
2013-10-03
A chemical found in red wine remains effective at fighting cancer even after the body's metabolism has converted it into other compounds.
This is an important finding in a new paper published in the journal Science Translational Medicine by Cancer Research UK-funded researchers at the University of Leicester's Department of Cancer Studies and Molecular Medicine.
The paper reveals that resveratrol – a compound extracted from the skins of red grapes – is not rendered ineffective once it is metabolised by the body.
This is an important development, as resveratrol is ...
Tears for fears
2013-10-03
Nocturnal animals need their noses to stay alive. Mice, among others, depend on their impressive olfactory powers to sniff out food or avoid danger in the dark.
Hard-wired to flee a predator or fight a mating rival in response to a whiff of urine, mice use a streamlined system that sends the sensory cue to neural centers in the brain that need only a few synapses to rapidly initiate the instinctive behavior. By comparison, the visual system on which humans rely to sense a threat must process many more variables, detecting the edges and colors and contrast of that looming ...
Longline fishery in Costa Rica kills thousands of sea turtles and sharks
2013-10-03
PHLADELPHIA (October 2, 2013)—The second-most-common catch on Costa Rica's longline fisheries in the last decade was not a commercial fish species. It was olive ridley sea turtles. These lines also caught more green turtles than most species of fish.
These findings and more, reported in a new study in the Journal of Experimental Marine Biology and Ecology, indicate that the Costa Rican longline fishery represents a major threat to the survival of eastern Pacific populations of sea turtles as well as sharks.
The researchers argue that time and area closures for the fisheries ...
October GSA Today: Earth upon Impact
2013-10-03
Boulder, Colorado, USA – In the October issue of GSA Today, Grant Young of the University of Western Ontario discusses the possible causes of the numerous glaciations that characterized the Neoproterozoic and concludes that a dramatic shift in Earth's climate may have occurred during the Ediacaran, in part due to a large marine impact. According to Young, this shift separates Proterozoic glaciations, which were likely triggered by the effect of supercontinent assembly and breakup on atmospheric carbon dioxide levels.
Young notes that this suggests strong seasonality ...
LAST 30 PRESS RELEASES:
Exotic observations with neutrons at the ILL
Scientists discover new gene-to-gene interaction increasing risk of alopecia
Chinese scientists find key genes to fight against crop parasites
Lung cancer cells can go ‘off grid’
An RNA inhibitor may effectively reduce a high-risk type of cholesterol in patients with cardiovascular disease
Research spotlight: Mapping lesions that cause psychosis to a human brain circuit and proposed stimulation target
New study identifies brain region that can prevent aggressive social behavior and induce pro social behavior
Telehealth may be closing the care gap for people with substance use disorder in rural areas
Stronger, safer, smarter: pioneering Zinc-based dissolvable implants for bone repair
Could peripheral neuropathy be stopped before it starts?
China Jurassic fossil discovery sheds light on bird origin
Long-term yogurt consumption tied to decreased incidence of certain types of colorectal cancer
Ovarian cancer discovery could turn failed treatment into lifesaver
DNA methylation clocks may require tissue-specific adjustments for accurate aging estimates
Tidal energy measurements help SwRI scientists understand Titan’s composition, orbital history
Data-driven networks influence convective-scale ensemble weather forecasts
Endocrine Society awards Baxter Prize to innovator in endocrine cancer drug discovery
Companies quietly switching out toxic product ingredients in response to California law
Can math save content creators? A new model proposes fairer revenue distribution methods for streaming services
Study examines grief of zoo employees and volunteers across the US after animal losses
National study underway to test new mechanical heart pump
Antarctica’s only native insect’s unique survival mechanism
How Earth's early cycles shaped the chemistry of life
Ukraine war forces planes to take longer routes, raising CO2
Negative refraction of light using atoms instead of metamaterials
High BP may develop at different ages and paces in East & South Asian adults in the UK
Meet the newly discovered brain cell that allows you to remember objects
Engineered animals show new way to fight mercury pollution
The 3,000-year coral reef shutdown: a mysterious pause and a remarkable recovery
Worm surface chemistry reveals secrets to their development and survival
[Press-News.org] International study shows efficacy of new gastric cancer drugThe phase III study published in the The Lancet shows that an antibody (ramucirumab) inhibits the action of various proteins involved in tumour growth, prolonging survival of patients with advanced gastric cancer